Loading…
Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data
•Acute adverse events after BNT162b2 vaccination in Saudi Arabia were extremely rare.•For each 10,000-dose administered, 48.4 events are estimated to occur.•Most common adverse events were dizziness, headache, nausea, and/or fatigue.•Female were significantly more likely to develop non-anaphylactic...
Saved in:
| Published in: | Vaccine 2022-01, Vol.40 (3), p.477-482 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c547t-67e5e4328662d4ebc066672d98de63070096232870691ae9fd11c222c5d851e93 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c547t-67e5e4328662d4ebc066672d98de63070096232870691ae9fd11c222c5d851e93 |
| container_end_page | 482 |
| container_issue | 3 |
| container_start_page | 477 |
| container_title | Vaccine |
| container_volume | 40 |
| creator | Almohaya, Abdulellah M. Alsubie, Haya Alqarni, Bader Alzayad, Bashayer Alghar, Ali Alshahrani, Khalid Barry, Mazin |
| description | •Acute adverse events after BNT162b2 vaccination in Saudi Arabia were extremely rare.•For each 10,000-dose administered, 48.4 events are estimated to occur.•Most common adverse events were dizziness, headache, nausea, and/or fatigue.•Female were significantly more likely to develop non-anaphylactic adverse events.•The vast majority of the adverse events were managed with short observation.
Acute adverse events and anaphylaxis were reported after the administration of coronavirus disease (COVID-19) mRNA vaccines. We aim to explore the nature and outcome of adverse events following BNT162B2 vaccine in a community vaccination center, Riyadh, Saudi Arabia.
Within 30 min post vaccination, all acute adverse events (AAEs) that occurred before March 31st, 2021, and in people older than 16 years were reviewed (AAE group). We used the case definition of Brighton collaboration on vaccine safety to define anaphylaxis. Patients’ demographics, comorbidities, allergy history, and outcome at disposition were collected. Observation duration after vaccination was short ( |
| doi_str_mv | 10.1016/j.vaccine.2021.12.001 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8668155</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X21016108</els_id><sourcerecordid>2618030633</sourcerecordid><originalsourceid>FETCH-LOGICAL-c547t-67e5e4328662d4ebc066672d98de63070096232870691ae9fd11c222c5d851e93</originalsourceid><addsrcrecordid>eNqFUU1v1DAQtRCILoWfALLEtQkzduwkF9BS8SVV5UCROGF57dniVRoXO0nVf19Xu1Rw4jSHeV96j7GXCDUC6je7erHOhZFqAQJrFDUAPmIr7FpZCYXdY7YCoZuqQfhxxJ7lvAMAJbF_yo5k06NGaFbs59rNE_F5zHEILkzkufULpUycFhqnzLdxGOJNGC_5-_ML1GIj-MGZh5F_s7MPfJ3sJtgTbnkiO1Q3MQ2eezvZ5-zJ1g6ZXhzuMfv-8cPF6efq7OunL6frs8qppp0q3ZKiRopOa-Eb2jjQWrfC950nLaEF6LUo7xZ0j5b6rUd0QginfKeQennM3u51r-fNFXlXkic7mOsUrmy6NdEG8-9nDL_MZVxMcexQqSLw-iCQ4u-Z8mR2cU5jyWyExg4kaCkLSu1RLsWcE20fHBDM_SxmZw7lmPtZDApTZim8V3_He2D92aEA3u0BVEpaAiWTXaDRkQ-J3GR8DP-xuANwXJ_N</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2618030633</pqid></control><display><type>article</type><title>Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data</title><source>Elsevier</source><creator>Almohaya, Abdulellah M. ; Alsubie, Haya ; Alqarni, Bader ; Alzayad, Bashayer ; Alghar, Ali ; Alshahrani, Khalid ; Barry, Mazin</creator><creatorcontrib>Almohaya, Abdulellah M. ; Alsubie, Haya ; Alqarni, Bader ; Alzayad, Bashayer ; Alghar, Ali ; Alshahrani, Khalid ; Barry, Mazin</creatorcontrib><description>•Acute adverse events after BNT162b2 vaccination in Saudi Arabia were extremely rare.•For each 10,000-dose administered, 48.4 events are estimated to occur.•Most common adverse events were dizziness, headache, nausea, and/or fatigue.•Female were significantly more likely to develop non-anaphylactic adverse events.•The vast majority of the adverse events were managed with short observation.
Acute adverse events and anaphylaxis were reported after the administration of coronavirus disease (COVID-19) mRNA vaccines. We aim to explore the nature and outcome of adverse events following BNT162B2 vaccine in a community vaccination center, Riyadh, Saudi Arabia.
Within 30 min post vaccination, all acute adverse events (AAEs) that occurred before March 31st, 2021, and in people older than 16 years were reviewed (AAE group). We used the case definition of Brighton collaboration on vaccine safety to define anaphylaxis. Patients’ demographics, comorbidities, allergy history, and outcome at disposition were collected. Observation duration after vaccination was short (<15 min) or extended (<3 h). Statistical analysis was performed to study AAEs association with the study variables and outcomes.
Out of 71,221 vaccine recipients, 144 (0.002%) had developed 345 AAEs, at a rate of 48.4 events per 10,000 dose administered. The majority of cases in AAE group were first dose recipients (93.8%) and previously healthy (59%), while the minority had a previous history of allergy (6.3%) or a laboratory-confirmed COVID-19 (4.2%). We found a significant association between female gender and the occurrence of any AAE (p-value = 0.002). Per every 10,000 doses administered, non-anaphylactic AAEs were dizziness (17.8), headache (9.7), nausea (7.1), or syncope (3.2). Only one in every ten AAEs was considered serious and resulted in an extended observation (4.8 per 10,000 doses), but only 1/144 required hospitalization for non-anaphylaxis reasons (0.1 per 10,000 doses). According to the Brighton collaboration definition of anaphylaxis, no single case of high certainty anaphylaxis was recorded. No death was documented in this cohort.
Acute adverse events due toBNT162b2 vaccinewere rare andmostlynon-seriouswith a tendency to occur more in women. Further prospectivestudieson largervaccine recipientsto evaluatethe incidenceof anaphylaxis in the Saudi population are warranted.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2021.12.001</identifier><identifier>PMID: 34916104</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adverse events ; Allergies ; Anaphylaxis ; Anaphylaxis - chemically induced ; Anaphylaxis - epidemiology ; Blood pressure ; BNT162 Vaccine ; Collaboration ; Comorbidity ; Contraindications ; Coronavirus ; Coronaviruses ; COVID-19 ; COVID-19 vaccines ; Demographics ; Demography ; Dosage ; Drug dosages ; Female ; Humans ; Immunization ; Medical laboratories ; mRNA ; mRNA Vaccines ; Nanoparticles ; Nausea ; Novel ; Safety ; SARS-CoV-2 ; Saudi Arabia - epidemiology ; Severe acute respiratory syndrome coronavirus 2 ; Statistical analysis ; Syncope ; Vaccine ; Vaccines ; Viral diseases ; Vital signs</subject><ispartof>Vaccine, 2022-01, Vol.40 (3), p.477-482</ispartof><rights>2021 Elsevier Ltd</rights><rights>Copyright © 2021 Elsevier Ltd. All rights reserved.</rights><rights>2021. Elsevier Ltd</rights><rights>2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c547t-67e5e4328662d4ebc066672d98de63070096232870691ae9fd11c222c5d851e93</citedby><cites>FETCH-LOGICAL-c547t-67e5e4328662d4ebc066672d98de63070096232870691ae9fd11c222c5d851e93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34916104$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Almohaya, Abdulellah M.</creatorcontrib><creatorcontrib>Alsubie, Haya</creatorcontrib><creatorcontrib>Alqarni, Bader</creatorcontrib><creatorcontrib>Alzayad, Bashayer</creatorcontrib><creatorcontrib>Alghar, Ali</creatorcontrib><creatorcontrib>Alshahrani, Khalid</creatorcontrib><creatorcontrib>Barry, Mazin</creatorcontrib><title>Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•Acute adverse events after BNT162b2 vaccination in Saudi Arabia were extremely rare.•For each 10,000-dose administered, 48.4 events are estimated to occur.•Most common adverse events were dizziness, headache, nausea, and/or fatigue.•Female were significantly more likely to develop non-anaphylactic adverse events.•The vast majority of the adverse events were managed with short observation.
Acute adverse events and anaphylaxis were reported after the administration of coronavirus disease (COVID-19) mRNA vaccines. We aim to explore the nature and outcome of adverse events following BNT162B2 vaccine in a community vaccination center, Riyadh, Saudi Arabia.
Within 30 min post vaccination, all acute adverse events (AAEs) that occurred before March 31st, 2021, and in people older than 16 years were reviewed (AAE group). We used the case definition of Brighton collaboration on vaccine safety to define anaphylaxis. Patients’ demographics, comorbidities, allergy history, and outcome at disposition were collected. Observation duration after vaccination was short (<15 min) or extended (<3 h). Statistical analysis was performed to study AAEs association with the study variables and outcomes.
Out of 71,221 vaccine recipients, 144 (0.002%) had developed 345 AAEs, at a rate of 48.4 events per 10,000 dose administered. The majority of cases in AAE group were first dose recipients (93.8%) and previously healthy (59%), while the minority had a previous history of allergy (6.3%) or a laboratory-confirmed COVID-19 (4.2%). We found a significant association between female gender and the occurrence of any AAE (p-value = 0.002). Per every 10,000 doses administered, non-anaphylactic AAEs were dizziness (17.8), headache (9.7), nausea (7.1), or syncope (3.2). Only one in every ten AAEs was considered serious and resulted in an extended observation (4.8 per 10,000 doses), but only 1/144 required hospitalization for non-anaphylaxis reasons (0.1 per 10,000 doses). According to the Brighton collaboration definition of anaphylaxis, no single case of high certainty anaphylaxis was recorded. No death was documented in this cohort.
Acute adverse events due toBNT162b2 vaccinewere rare andmostlynon-seriouswith a tendency to occur more in women. Further prospectivestudieson largervaccine recipientsto evaluatethe incidenceof anaphylaxis in the Saudi population are warranted.</description><subject>Adverse events</subject><subject>Allergies</subject><subject>Anaphylaxis</subject><subject>Anaphylaxis - chemically induced</subject><subject>Anaphylaxis - epidemiology</subject><subject>Blood pressure</subject><subject>BNT162 Vaccine</subject><subject>Collaboration</subject><subject>Comorbidity</subject><subject>Contraindications</subject><subject>Coronavirus</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Demographics</subject><subject>Demography</subject><subject>Dosage</subject><subject>Drug dosages</subject><subject>Female</subject><subject>Humans</subject><subject>Immunization</subject><subject>Medical laboratories</subject><subject>mRNA</subject><subject>mRNA Vaccines</subject><subject>Nanoparticles</subject><subject>Nausea</subject><subject>Novel</subject><subject>Safety</subject><subject>SARS-CoV-2</subject><subject>Saudi Arabia - epidemiology</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Statistical analysis</subject><subject>Syncope</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Viral diseases</subject><subject>Vital signs</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqFUU1v1DAQtRCILoWfALLEtQkzduwkF9BS8SVV5UCROGF57dniVRoXO0nVf19Xu1Rw4jSHeV96j7GXCDUC6je7erHOhZFqAQJrFDUAPmIr7FpZCYXdY7YCoZuqQfhxxJ7lvAMAJbF_yo5k06NGaFbs59rNE_F5zHEILkzkufULpUycFhqnzLdxGOJNGC_5-_ML1GIj-MGZh5F_s7MPfJ3sJtgTbnkiO1Q3MQ2eezvZ5-zJ1g6ZXhzuMfv-8cPF6efq7OunL6frs8qppp0q3ZKiRopOa-Eb2jjQWrfC950nLaEF6LUo7xZ0j5b6rUd0QginfKeQennM3u51r-fNFXlXkic7mOsUrmy6NdEG8-9nDL_MZVxMcexQqSLw-iCQ4u-Z8mR2cU5jyWyExg4kaCkLSu1RLsWcE20fHBDM_SxmZw7lmPtZDApTZim8V3_He2D92aEA3u0BVEpaAiWTXaDRkQ-J3GR8DP-xuANwXJ_N</recordid><startdate>20220124</startdate><enddate>20220124</enddate><creator>Almohaya, Abdulellah M.</creator><creator>Alsubie, Haya</creator><creator>Alqarni, Bader</creator><creator>Alzayad, Bashayer</creator><creator>Alghar, Ali</creator><creator>Alshahrani, Khalid</creator><creator>Barry, Mazin</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20220124</creationdate><title>Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data</title><author>Almohaya, Abdulellah M. ; Alsubie, Haya ; Alqarni, Bader ; Alzayad, Bashayer ; Alghar, Ali ; Alshahrani, Khalid ; Barry, Mazin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c547t-67e5e4328662d4ebc066672d98de63070096232870691ae9fd11c222c5d851e93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adverse events</topic><topic>Allergies</topic><topic>Anaphylaxis</topic><topic>Anaphylaxis - chemically induced</topic><topic>Anaphylaxis - epidemiology</topic><topic>Blood pressure</topic><topic>BNT162 Vaccine</topic><topic>Collaboration</topic><topic>Comorbidity</topic><topic>Contraindications</topic><topic>Coronavirus</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Demographics</topic><topic>Demography</topic><topic>Dosage</topic><topic>Drug dosages</topic><topic>Female</topic><topic>Humans</topic><topic>Immunization</topic><topic>Medical laboratories</topic><topic>mRNA</topic><topic>mRNA Vaccines</topic><topic>Nanoparticles</topic><topic>Nausea</topic><topic>Novel</topic><topic>Safety</topic><topic>SARS-CoV-2</topic><topic>Saudi Arabia - epidemiology</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Statistical analysis</topic><topic>Syncope</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Viral diseases</topic><topic>Vital signs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Almohaya, Abdulellah M.</creatorcontrib><creatorcontrib>Alsubie, Haya</creatorcontrib><creatorcontrib>Alqarni, Bader</creatorcontrib><creatorcontrib>Alzayad, Bashayer</creatorcontrib><creatorcontrib>Alghar, Ali</creatorcontrib><creatorcontrib>Alshahrani, Khalid</creatorcontrib><creatorcontrib>Barry, Mazin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>ProQuest Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Almohaya, Abdulellah M.</au><au>Alsubie, Haya</au><au>Alqarni, Bader</au><au>Alzayad, Bashayer</au><au>Alghar, Ali</au><au>Alshahrani, Khalid</au><au>Barry, Mazin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2022-01-24</date><risdate>2022</risdate><volume>40</volume><issue>3</issue><spage>477</spage><epage>482</epage><pages>477-482</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•Acute adverse events after BNT162b2 vaccination in Saudi Arabia were extremely rare.•For each 10,000-dose administered, 48.4 events are estimated to occur.•Most common adverse events were dizziness, headache, nausea, and/or fatigue.•Female were significantly more likely to develop non-anaphylactic adverse events.•The vast majority of the adverse events were managed with short observation.
Acute adverse events and anaphylaxis were reported after the administration of coronavirus disease (COVID-19) mRNA vaccines. We aim to explore the nature and outcome of adverse events following BNT162B2 vaccine in a community vaccination center, Riyadh, Saudi Arabia.
Within 30 min post vaccination, all acute adverse events (AAEs) that occurred before March 31st, 2021, and in people older than 16 years were reviewed (AAE group). We used the case definition of Brighton collaboration on vaccine safety to define anaphylaxis. Patients’ demographics, comorbidities, allergy history, and outcome at disposition were collected. Observation duration after vaccination was short (<15 min) or extended (<3 h). Statistical analysis was performed to study AAEs association with the study variables and outcomes.
Out of 71,221 vaccine recipients, 144 (0.002%) had developed 345 AAEs, at a rate of 48.4 events per 10,000 dose administered. The majority of cases in AAE group were first dose recipients (93.8%) and previously healthy (59%), while the minority had a previous history of allergy (6.3%) or a laboratory-confirmed COVID-19 (4.2%). We found a significant association between female gender and the occurrence of any AAE (p-value = 0.002). Per every 10,000 doses administered, non-anaphylactic AAEs were dizziness (17.8), headache (9.7), nausea (7.1), or syncope (3.2). Only one in every ten AAEs was considered serious and resulted in an extended observation (4.8 per 10,000 doses), but only 1/144 required hospitalization for non-anaphylaxis reasons (0.1 per 10,000 doses). According to the Brighton collaboration definition of anaphylaxis, no single case of high certainty anaphylaxis was recorded. No death was documented in this cohort.
Acute adverse events due toBNT162b2 vaccinewere rare andmostlynon-seriouswith a tendency to occur more in women. Further prospectivestudieson largervaccine recipientsto evaluatethe incidenceof anaphylaxis in the Saudi population are warranted.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>34916104</pmid><doi>10.1016/j.vaccine.2021.12.001</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2022-01, Vol.40 (3), p.477-482 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8668155 |
| source | Elsevier |
| subjects | Adverse events Allergies Anaphylaxis Anaphylaxis - chemically induced Anaphylaxis - epidemiology Blood pressure BNT162 Vaccine Collaboration Comorbidity Contraindications Coronavirus Coronaviruses COVID-19 COVID-19 vaccines Demographics Demography Dosage Drug dosages Female Humans Immunization Medical laboratories mRNA mRNA Vaccines Nanoparticles Nausea Novel Safety SARS-CoV-2 Saudi Arabia - epidemiology Severe acute respiratory syndrome coronavirus 2 Statistical analysis Syncope Vaccine Vaccines Viral diseases Vital signs |
| title | Acute unsolicited adverse events following BNT162b2 vaccine in Saudi Arabia, a real-world data |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T06%3A44%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20unsolicited%20adverse%20events%20following%20BNT162b2%20vaccine%20in%20Saudi%20Arabia,%20a%20real-world%20data&rft.jtitle=Vaccine&rft.au=Almohaya,%20Abdulellah%20M.&rft.date=2022-01-24&rft.volume=40&rft.issue=3&rft.spage=477&rft.epage=482&rft.pages=477-482&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2021.12.001&rft_dat=%3Cproquest_pubme%3E2618030633%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c547t-67e5e4328662d4ebc066672d98de63070096232870691ae9fd11c222c5d851e93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2618030633&rft_id=info:pmid/34916104&rfr_iscdi=true |